Coeptis Therapeutics Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Coeptis Therapeutics Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Aug 16, 2024 |
| FY2022 | Dec 31, 2021 | $75.0K | Mar 25, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.92M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($10.68M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($21.27M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($37.57M) | Aug 16, 2024 |
| FY2022 | Dec 31, 2021 | ($13.45M) | Mar 25, 2024 |
| FY2021 | Dec 31, 2020 | ($17.28M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($2.2K) | Feb 2, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.04M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($10.05M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($21.49M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($34.20M) | Aug 16, 2024 |
| FY2022 | Dec 31, 2021 | ($14.05M) | Mar 25, 2024 |
| FY2021 | Dec 31, 2020 | ($68.4K) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($2.2K) | Feb 2, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.15M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $8.91M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $4.57M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $7.92M | Aug 16, 2024 |
| FY2022 | Dec 31, 2021 | $6.77M | Mar 25, 2024 |
| FY2021 | Dec 31, 2020 | $76.71M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $171.5K | Feb 2, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.09M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $5.04M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $3.76M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $3.46M | Aug 16, 2024 |
| FY2022 | Dec 31, 2021 | $4.41M | Mar 25, 2024 |
| FY2021 | Dec 31, 2020 | $22.96M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $155.9K | Feb 2, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.56M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.38M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $814.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $4.45M | Aug 16, 2024 |
| FY2023 | Dec 31, 2021 | $2.35M | Aug 16, 2024 |
| FY2022 | Dec 31, 2020 | ($5.14M) | Mar 25, 2024 |
| FY2021 | Dec 31, 2019 | $15.7K | Apr 8, 2022 |
| FY2020 | Dec 31, 2018 | $17.9K | Feb 2, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (16) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Aug 16, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 25, 2024 |
| FY2021 | Dec 31, 2020 | (5) | Apr 8, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (16) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Aug 16, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 25, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $404.3K | Apr 8, 2022 |
| FY2021 | Dec 31, 2020 | $907.2K | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $505 | Feb 2, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.13M | Aug 16, 2024 |
| FY2022 | Dec 31, 2022 | $150.0K | Mar 25, 2024 |